Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coasts prime biotech hub in South San Francisco.
About Earli
The mission of the Biotechnology startup Earli Inc. is large and ambitious: to detect and then cure cancer at its earliest stages, effortlessly and pain free. In other words, make cancer a benign experience. The technology which grounds the companys efforts ushers in a new era in synthetic biomarkers as a novel methodology to detect cancer and then subsequently localize and then treat the cancer. The enabling technology utilizes synthetic biomarkers as a novel methodology to detect, localize and ultimately destroy cancer. Founded by Sam Gambhir, Cyriac Roeding and David Suhy, the company is well funded by world-class entrepreneurs and venture capital firms. Earli, Inc. is currently based in Redwood City, California.
Who You Are
The Position
Earli is seeking a highly motivated and committed Research Associate or Senior Research Associate for our In-Vivo Biology team.
Your Primary Responsibilities
Your Required Experience, Knowledge and Skill
If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.
We look forward to hearing from you!
About Earli
The mission of the Biotechnology startup Earli Inc. is large and ambitious: to detect and then cure cancer at its earliest stages, effortlessly and pain free. In other words, make cancer a benign experience. The technology which grounds the companys efforts ushers in a new era in synthetic biomarkers as a novel methodology to detect cancer and then subsequently localize and then treat the cancer. The enabling technology utilizes synthetic biomarkers as a novel methodology to detect, localize and ultimately destroy cancer. Founded by Sam Gambhir, Cyriac Roeding and David Suhy, the company is well funded by world-class entrepreneurs and venture capital firms. Earli, Inc. is currently based in Redwood City, California.
Who You Are
The Position
Earli, Inc. is currently seeking a dynamic Senior/Research Associate who is inspired to change the world by pushing the scientific envelope.
Your Primary Responsibilities
Your Required Experience, Knowledge and Skills
If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.
We look forward to hearing from you!
About Earli
The mission of the Biotechnology startup Earli Inc. is large and ambitious: to detect and then cure cancer at its earliest stages, effortlessly and pain free. In other words, make cancer a benign experience. The technology which grounds the companys efforts ushers in a new era in synthetic biomarkers as a novel methodology to detect cancer and then subsequently localize and then treat the cancer. ?The enabling technology utilizes synthetic biomarkers as a novel methodology to detect, localize and ultimately destroy cancer. ? Founded by Sam Gambhir, Cyriac Roeding and David Suhy, the company is well funded by world-class entrepreneurs and venture capital firms. Earli, Inc. is currently based in Redwood City, California.?
Who You Are
The Position
This is a general interest application if you are interested in working at Earli but don't see a current opening that aligns with your skills and background. We're growing and always on the lookout for great people who are interested in working with us or who are interested in potential upcoming internship opportunities available in our lab.
If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.
We look forward to hearing from you!